The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...
In 2016, a 65-year-old woman presenting with skin thickening and Raynaud phenomenon was referred to a rheumatologist with a suspicion of systemic sclerosis (SSc). Her modified Rodnan skin score was 18 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results